Will the FDA Give These Drugs a Thumbs Up?

In the following video, Motley Fool health-care bureau chief Brenton Flynn takes a look at two different companies with drugs facing FDA approval decisions in February. He discusses ImmunoGen (NASDAQ: IMGN  ) and its drug T-DM1, where approval is already expected by the market, as well as Dynavax (NASDAQ: DVAX  ) and its hepatitis B vaccine Heplisav. Dynavax is the wildcard of this group, and Brenton gives his prediction for whether or not the drug will be approved.

A Massive New Market
While Dynavax awaits its fate in Hepatitis B, another company is hoping to strike it rich with a revolutionary new cure for the widespread Hepatitis C virus. The opportunity is huge, and its one AbbVie will need, becaus its cash cow, Humira, will eventually go to the patent slaughterhouse. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking; and, as an added bonus, you'll receive a full year of free analyst updates as significant news hits. Simply click here now to claim your copy today.


Read/Post Comments (1) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2243963, ~/Articles/ArticleHandler.aspx, 10/24/2014 3:16:51 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement